Market Flash: iSHARES MSCI Indonesia Investable Market Index Fund (EIDO:US) PRICE: 28.530 USD Down -0.360 (-1.246%) >>> BI: Rupiah Melemah Akibat Kondisi Eropa >>> Pertemuan FED pertimbangkan langkah baru dorong ekonomi >>> KIJA akan Terbitkan MEN Valas USD150 Juta >>> PT Indika Energy Perusahaan Teladan Dunia 2011 >>> Govt Promises Revision of Cost Recovery Regulation >>> BPMigas Demands PGN to Pay US$6 per MMBTU >>> Jababeka to Raise US$150 Million from Debt Markets >>> SCG Chemicals buys Chandra Asri >>> Solusi Tunas eyes Rp380 bio IPO >>> SMR Utama scouts Rp300 bio IPO >>> Alam Sutera picks two bond arrangers >>> ASII Tetap Rajai Penjualan Mobil Agustus 2011 >>> Perusahaan Thailand kuasai Saham TPIA senilai Rp 3,76 Triliun >>> Agis Main ke Tambang, Sahamnya Masuk Dalam Pengawasan >>> ACES Mendekati The Northern Agar Mau Kurangi Kepemilikan >>> IHSG masih harus berjuang terus bertahan diatas MA200 >>> Melirik Peluang Akumulasi di Saham Perbankan >>> Analisa Saham BUMI: Kuat Bertahan & Berpeluang Kembali Uptrend >>> Analisa Saham JSMR: Bertahan Di Support, What Next? >>> INDF Tertahan Di Area Support Kuat, Berpeluang Rebound >>> ASII Break Minor Support, Sell on Strength >>> ADRO Membentuk Descending Wedges, Berpeluang Rebound Terbatas >>> Wall Street ends flat as early gains evaporate >>> Fed begins policy meeting, tiptoes toward easing >>> Fed meeting to help decide on long-term Treasuries >>> Greece Makes 'Good Progress' in Reform Talks: EC >>> China worried Europe debt crisis will hit trade >>> China could roll out 4.65tr yuan stimulus package >>> IMF sees Mideast stagnation >>> NYMEX-Crude ends higher at Oct contract expiry >>> Asian Crude Palm Oil Up On Technical Buying, Soyoil >>> Foreign net Sell - 61.785.746

Kamis, 17 Februari 2011

Kimia Farma FY10 net income up 61.44% - Insider Stories

The state-owned drug producer PT Kimia Farma Tbk (KAEF) estimated to post FY2010's net income of Rp100.9 billion, a 61.44% jump from Rp62.5 billion in the end of 2009.
Kimia Farma President Director Kimia Farma Syamsul Arifin said that such profit jump is expected to realize following the 6.31% revenue jump, from Rp2.85 trillion in 2009 to Rp3.03 trillion in the end of 2010.

Meanwhile, this year, the company seeks to record 10.89% revenue growth to Rp3.36 trillion compared to the same period in the previous year.
Syamsul said that the company owns three business units, including drug stores, trading and manufacture industry. Until now the contribution from sales is still higher compared to drug stores and trading. For the profit, manufacture industry somehow still dominates.
“In term of sales, the biggest contributors are trading and distribution while in terms of profit the industrial sector gave the biggest contribution up to 77%,” he explained.
Posted by Saham Pilihan at 23.15

Tidak ada komentar:

Posting Komentar

Langganan: Posting Komentar (Atom)